SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as community members actively engage with the coin's meme-driven identity, asking 'What's Updog?' and highlighting its presence on the Solana blockchain. The community emphasizes its long-term development, locked liquidity, and status as a 'joke meta pioneer' within the crypto space, encouraging others to load up on $SOL.X.

Pitbull

Pitbull ($PIT.X) is trending as the community celebrates recent visibility boosts, including trending on Stocktwits and Dextools, highlighting its community-driven nature and decentralized structure with no team wallet. The "Pitbull Army" is rallying around the token's unique features and long-term growth potential, drawing comparisons to other successful meme coins in the crypto space. Recent volume surges and increased activity on platforms like LBank are also fueling the conversation.

TOSHI

TOSHI.X is trending amid excitement around new exchange listings, particularly in South Korea, and anticipation of potential future listings on major platforms like Binance and OKX. The community is buzzing with bullish sentiment, discussing potential rallies and the possibility of "dropping a zero" from the price, while also noting a partnership with Coinbase. Technical analysis and whale activity are also being closely watched as potential catalysts for further upward movement.

Orderly Network is a L2 built on OP stack delivering a permissionless liquidity layer for Web3 trading, with one shared orderbook across different blockchains — powered by Orderly Chain and LayerZero. Our mission is to empower trading on any chain, any asset, any interface. Orderly offers spot and perpetual futures orderbooks trading across Arbitrum, Optimism, Polygon, Base ,Mantle and Near, while expanding to other blockchains.

Orderly Network

Orderly Network is trending as the community anticipates news this week, with some users suggesting a breakout is imminent. Conversations highlight the potential for significant upward movement and the project's appeal as a potentially reliable investment in the crypto space. Some users are noting a current price pump.

BlackBerry Ltd

BlackBerry is trending as the community discusses its QNX technology's growing presence in the automotive and robotics industries, particularly its integration with NVIDIA's DRIVE AGX Thor platform. Investors are optimistic about potential revenue growth from royalty backlogs and partnerships, highlighting the company's transition towards secure communications and embedded systems. The community speculates on a possible QNX spin-off, believing that this move would increase shareholder value.

Breaking Bread

Breaking Bread ($BRBR.X) is trending due to its innovative rewards system on Pumpfun, which is generating significant community excitement. The absence of transaction taxes, coupled with a mechanism that redistributes creator rewards back to holders, is a key talking point. Investors are drawn to the potential for passive income within this novel framework.

MATH is a one stop crypto solution platform which contains MathWallet, MATH VPOS Pool, MathDEX, MATH dApp Store, MATH Staking, MATH Pay, MATH Chain, etc.

MATH

MATH.X is trending as traders discuss its potential for a pump, citing its low market cap and history of significant price swings. Some community members are speculating about a breakout, while others remain skeptical, pointing to past disappointments and ongoing selling pressure. Discussion includes potential price targets and the impact of overall crypto market trends.

Binance Coin is the cryptocurrency of the Binance platform. It is a trading platform exclusively for cryptocurrencies. The name "Binance" is a combination of binary and finance.  Thus, the startup name shows that only cryptocurrencies can be traded against each other. It is not possible to trade crypto currencies against Fiat. The platform achieved an enormous success within a very short time and is focused on worldwide market with Malta headquarters. The cryptocurrency currently has a daily trading volume of 1.5 billion - 2 billion US dollars and is still increasing.  In total, there will only be 200 million BNBs. Binance uses the ERC20 token standard from Ethereum and has distributed it as follow: 50% sold on ICO, 40% to the team and 10% to Angel investors. The coin can be used to pay fees on Binance. These include trading fees, transaction fees, listing fees and others. Binance gives you a huge discount when fees are paid in BNB.   The schedule of BNB fees discount is as follow: In the first year, 50% discount on all fees, second year 25% discount, third year 12.5% discount, fourth year 6.75 % discount, and from the fifth year onwards there is no discount. This structure is used to incentivize users to buy BNB and do trades within Binance.  Binance announced in a buyback plan that it would buy back up to 100 million BNB in Q1 2018. The coins are then burned. This means that they are devaluated to increase the value of the remaining coins. This benefits investors. In the future, the cryptocurrency will remain an asset on the trading platform and will be used as gas.  Other tokens that are issued by exchanges include Bibox Token, OKB, Huobi Token, and more.

Binance

Binance Coin is trending amid discussions of its strong performance and potential new all-time highs, with some community members suggesting it's undervalued compared to other exchange tokens; conversations also mention potential integrations with other projects and speculation around upcoming catalysts.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu is trending as its community rallies around the token's potential, emphasizing its strong base and promising future within the meme coin landscape. Discussions highlight the return of key figures and the development team's commitment, with some comparing it to the early days of Shiba Inu. Community members express conviction in the token's long-term growth and anticipate significant gains.

Hege is on a quest to become a successful meme in order to win the heart of his crush, Hegena.  Join the $HEGE-fund to help turn Hege's dream into reality!  The Hege story features 10 chapters, that are unlocked at various market cap goals, ranging from $1m-$1b.  NFT's, airdrops, rewards and more are also unlocked at the release of every chapter!  Hege is on a quest to become a successful meme in order to win the heart of his crush, Hegena.  Join the $HEGE-fund to help turn Hege's dream into reality!  The Hege story features 10 chapters, that are unlocked at various market cap goals, ranging from $1m-$1b.  NFT's, airdrops, rewards and more are also unlocked at the release of every chapter!

Hege

$HEGE.X is trending as the community anticipates a major announcement regarding marketing plans, CEX listings, and upcoming events, fueling excitement around the project's potential. Community members express strong bullish sentiment, citing the active development team, engaged community, and unique brand identity as key drivers. Discussions highlight the potential for significant growth and a breakout to new all-time highs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Analysts delivered mixed verdicts on Eli Lilly after the drugmaker released late-stage trial results for its investigational oral weight-loss drug Orforglipron, sending shares sharply lower on Thursday.<a href="https://stocktwits.com/symbol/LLY">Eli Lilly shares</a> closed down 14.1% at $640.86 on Thursday,&nbsp;their worst session since Aug. 9, 2000,&nbsp;but climbed in after-hours trading. The stock is now at lows last seen in early 2024.Leerink downgraded Eli Lilly to ‘Market Perform’ from ‘Outperform’ and cut its price target to $715 from $944, calling the results “disappointing” and lowering its long-term projections.&nbsp;The firm stated that its investment thesis had&nbsp;shifted and no longer&nbsp;anticipated upward pressure on consensus estimates, warning of rising GLP-1 competition by the end of the decade, even as rival Novo Nordisk faces pricing pressure.BofA, by contrast, called Eli Lilly’s second quarter (Q2) earnings and FY25 guidance raise “refreshing” compared with Novo’s “troubled” quarter, saying the drop in Lilly’s stock was “way overdone” and created a buying opportunity.&nbsp;The bank kept its ‘Buy’ rating and $1,000 price target, saying Eli Lilly remains “in pole position in obesity.”The Phase 3 ATTAIN-1 trial in 3,127 adults with obesity or overweight showed patients on the highest 36 mg dose l<a href="https://stocktwits.com/news-articles/markets/equity/nifty-sensex-recover-to-end-in-green-august-7/chrmRMkRddF">ost an average of 12.4% of body weight</a>, or 27.3 pounds, at 72 weeks, with nearly 60% losing at least 10%.&nbsp;Lilly stated that safety was consistent with injectable GLP-1 drugs, such as Mounjaro. The company plans to seek regulatory approval by the end of the year.H.C. Wainwright’s Joseph Pantginis said Viking Therapeutics’ VK2735 “remains a standout” after comparing discontinuation rates favorably with Eli Lilly’s data. The firm reiterated its ‘Buy’ rating on Viking with a $102 target and raised its target for Structure Therapeutics to $75 from $60, citing the potential of its oral GLP-1 candidate aleniglipron.Eli Lilly also lifted its 2025 revenue guidance midpoint by $1.5 billion to $60 billion–$62 billion and now expects adjusted EPS of $21.75–$23.The company’s Q2 revenue jumped 38% to $15.56 billion, with $5.2 billion from Mounjaro and $3.38 billion from Zepbound. Adjusted EPS was $6.31, topping forecasts.On Stocktwits, retail sentiment for Eli Lilly, which was among the top three trending tickers, was ‘extremely bullish’ amid a 1,228% surge in 24-message volume.One user on Stocktwits said they believed Eli Lilly shares would rebound eventually, but not immediately, noting that with Friday approaching and the rest of the world yet to react, it might be better to wait before adding more calls or shares.<stembedurl>https://stocktwits.com/SIbilisWhisper/message/624244609</stembedurl>Another user commented that they had bought as much stock as they could, calling it “way oversold” despite what they viewed as an extremely bullish earnings report, adding that stock market makers “are a mystery.”<stembedurl>https://stocktwits.com/Mypointofbay/message/624237111</stembedurl>Eli Lilly’s stock has declined&nbsp;about 17% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound

A late-stage study tested three doses of Eli Lilly’s oral GLP-1 drug, Orforglipron, in more than 3,100 adults, with the highest dose resulting in an average weight loss of 27.3 pounds over 72 weeks.

Equity

Pfizer Inc.'s (PFE) decision to halt the development of its oral GLP-1 candidate due to a potential liver toxicity issue could pose tailwinds for smaller biotech rivals, according to Wall Street analysts.According to The Fly, JPMorgan thinks Pfizer's scrapping of its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pfizer-ends-development-of-weight-loss-pill-danuglipron/chfCPelRba2">danuglipron</a> program opens the door for Structure Therapeutics’ (GPCR)GSBR-1290 (aleniglipron) to become the second small molecule oral GLP-1 to reach the market.It also makes Viking Therapeutics' (VKTX) an "even more attractive partnership candidate," the analyst said.Meanwhile, BTIG also flagged Viking as a key beneficiary, reiterating its 'Buy' rating and $125 price target, implying a 400% upside from the last close.&nbsp;The research firm pointed to Viking's "competitive" oral candidate VK2735, currently in Phase 2 trials, with data expected in the second half of 2025.&nbsp;A Phase 3 study for the injectable form is also set to begin in the second quarter.Media reports suggest Pfizer could now look to external assets. BTIG said it remains focused on Viking's "compelling pipeline and data" regardless of Pfizer's next steps.Retail sentiment for Viking Therapeutics turned 'bullish' late Monday from 'bearish' a day ago, accompanied by an 8,220% surge in message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/VKTX_sentiment_and_message_volume_on_April_14_png_16bef741c1.webp" alt="VKTX sentiment and message volume on April 14.png" width="1318" height="316"><figcaption>VKTX sentiment and message volume on April 14. | source: Stocktwits</figcaption></figure>One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."<stembedurl>https://stocktwits.com/rxptgh/message/611544179</stembedurl>Another watcher speculated that Pfizer could likely buy Viking Therapeutics following the news.<stembedurl>https://stocktwits.com/KnysnaNow/message/611596706</stembedurl>Structure Therapeutics, meanwhile, saw its sentiment meter jump into 'extremely bullish' levels from 'bearish' a day ago.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/GPCR_sentiment_and_message_volume_on_April_14_png_6c34839d3e.webp" alt="GPCR sentiment and message volume on April 14.png" width="1318" height="316"><figcaption>GPCR sentiment and message volume on April 14. | source: Stocktwits</figcaption></figure>A bullish user said the company's aleniglipron "is going to be best in class" among GLP-1 oral pills, and CEO Ray Stevens "knows it's an easy winner and big money."<stembedurl>https://stocktwits.com/DAR2487/message/611630051</stembedurl>Structure's stock is down over 30% year to date, while Viking's has lost nearly 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."

Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish

Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.

 Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For Viking, Structure Therapeutics

Structure CEO on the competitive landscape for oral GLP-1 drugs

Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings...

Promising Outlook for Structure Therapeutics with Strong Pipeline and Financial Stability

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR Research Report) today and s...

Buy Rating Backed by Strategic Partnership Opportunities and Strong Patent Portfolio for Structure Therapeutics

Leerink Partners analyst David Risinger has reiterated their bullish stance on GPCR stock, giving a Buy rating on July 22. David Risinger has given...

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?

Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest...

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics...

Peering Into Structure Therapeutics's Recent Short Interest

Structure Therapeutics CEO on GLP drugs

Structure Therapeutics CEO on GLP drugs...

Ozempic competitors, psychedelic stocks, and Moderna after COVID: Pharma news roundup

Zealand Pharma and Structure Therapeutics both announced new clinical trial results for their experimental weight loss drugs. The stock of several psychedelic medicines companies fell on Wednesday...

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in February 2019 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$25.80
Prev Close	$23.23
Open	$23.22
Dividend Yield	0.00%
50-Day Moving Average	$19.21
Beta	1.05
Avg. Volume	847,074.71
PE Ratio	-7.54

52-Week High	$45.37
52-Week Low	$13.22
Market Capitalization	$1.36B
EPS (Annual)	-$2.33
Price to Book	1.76
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

GPCR
Structure Therapeutics Inc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GPCR News

GPCR Structure Therapeutics Inc - ADR